(Q53609100)

16 May 2018

title

Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs. (English)

1 reference

16 May 2018

main subject

visceral leishmaniasis

1 reference

0 references

Omar A Saldarriaga

1

1 reference

16 May 2018

Bruno L Travi

2

1 reference

16 May 2018

Won Park

3

1 reference

16 May 2018

Luis E Perez

4

1 reference

16 May 2018

Peter C Melby

5

1 reference

16 May 2018

language of work or name

English

0 references

publication date

9 November 2005

1 reference

16 May 2018

published in

Vaccine

1 reference

16 May 2018

volume

24

1 reference

16 May 2018

issue

11

1 reference

16 May 2018

page(s)

1928-1940

1 reference

16 May 2018

Canine leishmaniasis: identification of asymptomatic carriers by polymerase chain reaction and immunoblotting

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Leishmania infantum-specific IgG, IgG1 and IgG2 antibody responses in healthy and ill dogs from endemic areas. Evolution in the course of infection and after treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

The immunology of canine leishmaniosis: strong evidence for a developing disease spectrum from asymptomatic dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Leishmaniasis reservoirs and their significance in control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Studies on control of visceral leishmaniasis: impact of dog control on canine and human visceral leishmaniasis in Jacobina, Bahia, Brazil.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Infectiousness in a cohort of brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Effect of eliminating seropositive canines on the transmission of visceral leishmaniasis in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Activity of liposomal amphotericin B (AmBisome) in dogs naturally infected with Leishmania infantum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Decreased sensitivity to meglumine antimoniate (Glucantime) ofLeishmania infantumisolated from dogs after several courses of drug treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

An update on antileishmanial vaccine candidates and prospects for a canine Leishmania vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Leishmaniasis: current status of vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Vaccination against cutaneous leishmaniasis: current status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

DNA vaccine encoding nucleocapsid and surface proteins of wild type canine distemper virus protects its natural host against distemper

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Nucleic acid immunization protects dogs against challenge with virulent canine parvovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Immunization of dogs and cats with a DNA vaccine against rabies virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Immunization of animals: from DNA to the dinner plate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I.R. Iran

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (S�o Gon�alo do Amarante, RN)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Amplification of kinetoplast DNA as a tool in the detection and diagnosis of Leishmania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Polynucleotide vaccines in animals: enhancing and modulating responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

DNA vaccines: immunology, application, and optimization*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Infection of a canine macrophage cell line with leishmania infantum: determination of nitric oxide production and anti-leishmanial activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Rabies DNA vaccine in the horse: strategies to improve serological responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

The correlation between delayed hypersensitivity, lymphocyte activation and protective immunity in experimental murine leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Cutaneous leishmaniasis in the Peruvian Andes: an epidemiological study of infection and immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Immunological and histological study of T- and B-lymphocyte activity in canine visceral leishmaniosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Humoral and cell-mediated immunity in natural and experimental canine leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

The Ibizian hound presents a predominantly cellular immune response against natural Leishmania infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Leishmania infantum-specific T cell lines derived from asymptomatic dogs that lyse infected macrophages in a major histocompatibility complex-restricted manner.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Reduced immunogenicity of DNA vaccine plasmids in mixtures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Early parasite containment is decisive for resistance to Leishmania major infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Interferon gamma-independent effects of interleukin 12 administered during acute or established infection due to Leishmania major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

The role of CpG dinucleotides in DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Selective enhancement of the type 1 cytokine response by expression of a canine interleukin (IL)-12 fused heterodimeric DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

Cellular and humoral immune responses in dogs experimentally and naturally infected with Leishmania infantum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

7 January 2021

Coadministration of interleukin 12 expression vector with antigen 2 cDNA enhances induction of protective immunity against Coccidioides immitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

7 January 2021

The host response to Leishmania infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

7 January 2021

Natural and experimental re-infection of man with Oriental sore

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.052

7 January 2021

10.1016/J.VACCINE.2005.10.052

Identifiers

DOI

1 reference

16 May 2018

1 reference

16 May 2018